AU2010289643A1 - Pharmaceutical formulations for indibulin - Google Patents

Pharmaceutical formulations for indibulin Download PDF

Info

Publication number
AU2010289643A1
AU2010289643A1 AU2010289643A AU2010289643A AU2010289643A1 AU 2010289643 A1 AU2010289643 A1 AU 2010289643A1 AU 2010289643 A AU2010289643 A AU 2010289643A AU 2010289643 A AU2010289643 A AU 2010289643A AU 2010289643 A1 AU2010289643 A1 AU 2010289643A1
Authority
AU
Australia
Prior art keywords
oral formulation
formulation
disintegrant
diluent
indibulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010289643A
Other languages
English (en)
Inventor
John C. Amedio Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ziopharm Oncology Inc
Original Assignee
Ziopharm Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziopharm Oncology Inc filed Critical Ziopharm Oncology Inc
Publication of AU2010289643A1 publication Critical patent/AU2010289643A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2010289643A 2009-09-02 2010-09-01 Pharmaceutical formulations for indibulin Abandoned AU2010289643A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23925409P 2009-09-02 2009-09-02
US61/239,254 2009-09-02
PCT/US2010/047436 WO2011028743A1 (en) 2009-09-02 2010-09-01 Pharmaceutical formulations for indibulin

Publications (1)

Publication Number Publication Date
AU2010289643A1 true AU2010289643A1 (en) 2012-03-22

Family

ID=43649611

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010289643A Abandoned AU2010289643A1 (en) 2009-09-02 2010-09-01 Pharmaceutical formulations for indibulin

Country Status (7)

Country Link
US (1) US20120219597A1 (enExample)
EP (1) EP2473168A4 (enExample)
JP (1) JP2013503876A (enExample)
AU (1) AU2010289643A1 (enExample)
CA (1) CA2772871A1 (enExample)
TW (1) TW201113266A (enExample)
WO (1) WO2011028743A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
CN116531375A (zh) * 2023-06-06 2023-08-04 河北大学 一种tppp3抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
PT96229B (pt) * 1989-12-22 1998-06-30 Syntex Pharma Int Processo para a preparacao de composicoes farmaceuticas em po, secas por pulverizacao, directamente compressiveis em comprimidos, contendo naproxeno ou naproxeno sodico
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US20070098797A1 (en) * 2005-06-02 2007-05-03 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
ES2277767B1 (es) * 2005-11-04 2008-04-01 Simbec Iberica, S.L. Formas orales solidas de ebastina.
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation

Also Published As

Publication number Publication date
EP2473168A4 (en) 2013-04-10
WO2011028743A1 (en) 2011-03-10
TW201113266A (en) 2011-04-16
EP2473168A1 (en) 2012-07-11
US20120219597A1 (en) 2012-08-30
JP2013503876A (ja) 2013-02-04
CA2772871A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
AU2024205682B2 (en) Kinase Inhibitor Salts and Compositions thereof
US12138242B1 (en) Controlling neuropathic pain
KR20100017119A (ko) 특정 유기산을 함유하는 경구 제제, 및 경구 제제의 용출성과 화학적 안정성의 개선 방법
CN113440481B (zh) 伊布替尼的自微乳组合物
WO2023059817A1 (en) Hydrochloride salt of inupadenant, pharmaceutical compositions and methods of use thereof
JP2021512860A (ja) 薬学的製剤
EP1427392B1 (en) New self emulsifying drug delivery system
US20120219597A1 (en) Pharmaceutical formulations for indibulin
JP2017530162A (ja) Ａ−ノル−５αアンドロスタン化合物の経口投与製剤
CA2577310C (en) Methods and compositions for oral delivery of fts
RU2639482C2 (ru) Фармацевтические композиции
AU2006257428B2 (en) Oral solid pharmaceutical formulation of the tubulin inhibitor indibulin
AU2011276552B2 (en) Oral formulation of kinase inhibitors
RU2430718C2 (ru) Фармацевтическая композиция для перорального введения
WO2022248401A1 (en) A plurality of tasquinimod particles and use thereof
TW200423972A (en) Tablet having improved solubility
CN115943138A (zh) 包含gardos通道拮抗剂的组合物及其用途
CN119258224A (zh) 熊果酸和多靶点酪氨酸激酶受体抑制剂的药物组合
BR102018013710B1 (pt) Composição farmacêutica para dor neuropática
BRPI0614757A2 (pt) composição farmacêutica, micropartìcula e seu uso

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application